STAGING MCR Staff Show Me Healthy Women March

STAGING MCR Staff Show Me Healthy Women March 27, 2008 Supported by a Cooperative Agreement between DHSS and the Centers for Disease Control and Prevention (CDC) and a Surveillance Contract between DHSS and MU

Staging Grouping of cancer cases according to similar degrees of spread or extent of disease. Extent of disease is a detailed description of how far the tumor has spread from organ or site of origin (the primary site).

Staging n PURPOSES n Determine appropriate treatment n Predict prognosis n Evaluate results of treatment n Facilitate exchange of information n Contribute to research of human cancer

Staging Elements n Elements to be considered in any staging system are the n primary tumor site, n tumor size, n multiplicity (number of tumors), n depth of invasion and extension to regional or distant tissues, n involvement of regional lymph nodes, and n distant metastases.

Types of Staging Systems n Summary Staging n American Joint Committee on Cancer (AJCC) Staging System n Collaborative Staging n Others n FIGO (GYN) n Dukes (colorectal) n Ann Arbor ( Lymphoma)

FIGO n Acronym for the French term that means International Federation for Gynecology and Obstetrics. The American Joint Committee on Cancer has developed the tumor (T) component of the TNM staging system to correspond to FIGO staging.

How to? n Where did the cancer start? n Where did the cancer go? n How did the cancer get there? n What is the stage?

Staging Sources n Physical Exam n Radiologic Procedures n X-rays n Scans n Endoscopies n Tumor markers n Pathologic exams n Surgical reports n Progress Notes and Discharge Summaries

How Cancer Spreads n Local invasion n Direct extension n Lymphatic metastases n Blood-borne metastases n Intra-cavitary

Summary Staging 0 – in situ 1 – localized 2 – regional by direct extension only 3 – regional lymph nodes involved only 4 – regional by both direct extension and lymph node involvement n 5 – regional, NOS (not otherwise specified) n 7 - distant site(s)/node(s) involved n 9 – unknown (unstaged, unknown or unspecified) n n n

training. seer. cancer. gov

In Situ Terms n CIN III n Confined to epithelium n Intracystic, non-infiltrating n Intraductal n Intraepidermal n Intra-epithelial n Intrasquamous n Stage 0

In Situ Terms n Involvement up to but not including the basement membrane n Lobular neoplasia n Non-infiltrating n Non-invasive n No stromal invasion n Preinvasive

CIN III n CIN III (cervical intraepithelial neoplasia grade iii) must be carefully reviewed, because this diagnosis includes both carcinoma in situ and severe dysplasia.

Microinvasion n Microinvasion implies invasion through the basement membrane. The stage would be INVASIVE not insitu. n Any foci of invasion makes the stage invasive rather than insitu.

training. seer. cancer. gov

training. seer. cancer. gov

Distant n Distant mets can be by: ndirect contiguous extension nimplantation (discontinuous) mets nlymph node involvement

Unstageable n Unknown primaries n Not enough information to stage n Death certificate only

AJCC (TNM) Staging Louanne Currence, RHIT, CTR

What is TNM Staging? n Developed by physicians (AJCC) n Uniform staging system to determine treatment, prognosis & end results n T = Tumor n N = Nodes n M = Metastasis n Group Stage = summary of TNM

Clinical Staging n Used to select primary treatment n Each site has specific guidelines of what is acceptable under c. TNM Physical exam Radiology Endoscopy Biopsy

Pathologic Staging n Based on pre-treatment evidence and/or subsequent surgery/path n Used to n Determine adjuvant therapy n Estimate prognosis n Report end results

T n Primary "Tumor" and its contiguous extension n. Based on size (invasive only) n. Based on penetration n. Extension of primary

T n T-value increases with worsening scenario n. Tx - cannot assess n. T 0 - no evidence of primary n. Tis - In situ (never sarcomas) n. T 1 -4

Sample "T"s n < 1. 0 cm breast lesion = T 1 n 3. 0 cm LOQ breast lesion = T 2 n Carcinoma confined to uterus = T 1 n Cervical carcinoma extends to pelvic wall = T 3

N n Regional lymph nodes n. Absence or presence of + LN n# of + LNs/size of metastasis n. Laterality of + LNs/size of mets n Named LN chains

N n Increases in severity n. Nx - cannot assess n. N 0 - no regional LN mets n. N 1 -3

Sample "N"s n Breast n Metastasis in axillary LNs fixed or matted = N 2 n 1 of 15 axillary LNs + (breast) = N 1 n Cervix n 1 + pelvic node = N 1

M n Some sites have listing n Mx - cannot assess n M 0 - no distant mets n M 1 - distant mets found

Group Stage n Is the general reference point of comparison n Tis = Stage 0 n Stage I, Stage III, Stage IV

Group Stage Examples (Breast) Stage 0 Tis N 0 M 0 Stage I T 1 N 0 M 0 Stage IIA T 0 N 1 M 0 ~~~~~ Stage IIIB T 4 N 0 M 0 Stage IIIC Any T N 3 M 0 Stage IV Any T Any N M 1

Group Stage Samples (Cervix) Stage 0 Tis N 0 M 0 Stage I T 1 N 0 M 0 Stage IIA T 2 a ~~~~~ Stage IIIB T 1 N 1 M 0 T 2 N 1 M 0 Stage IV Any T Any N M 1

Collaborative Stage n Collaborative Staging (CS) data items n CS Extension n CS Lymph Nodes n CS Mets at Dx

Steps for Staging 1) Determine primary site & histology 3) Is histology included? 4) Review list of regional LNs 5) Review rules of classification 6) Find staging information in chart 7) Determine T, N, M and group stage

Exercises

Missouri Cancer Registry Help Line: 800 -392 -2829 n Help interpreting path report for staging http: //mcr. umh. edu n For further information, please contact: Sue Vest, Project Manager, vests@health. missouri. edu Nancy Cole, Assistant Project Manager colen@health. missouri. edu